Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (SHE:300357) — Stock Price
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (SHE:300357) is currently trading at CN¥25.01 CNY, up 0.52% today. Over the past 52 weeks, shares have ranged between CN¥20.83 and CN¥35.30. This page tracks Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's live share price on the SHE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) market capitalisation.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's daily closing share price and trading volume on the SHE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Income Statement — Revenue, Profit & Earnings by Year
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | CN¥925.39 Million | CN¥848.19 Million | CN¥896.02 Million | CN¥807.69 Million | CN¥636.21 Million |
| Cost of Revenue | CN¥44.81 Million | CN¥40.19 Million | CN¥42.51 Million | CN¥34.44 Million | CN¥28.54 Million |
| Gross Profit | CN¥880.58 Million | CN¥808.00 Million | CN¥853.50 Million | CN¥773.25 Million | CN¥607.67 Million |
| Research & Development | CN¥119.88 Million | CN¥112.20 Million | CN¥106.02 Million | CN¥87.93 Million | CN¥64.87 Million |
| SG&A | CN¥73.22 Million | CN¥62.11 Million | CN¥47.82 Million | CN¥51.86 Million | CN¥34.40 Million |
| Total Operating Expenses | CN¥511.47 Million | CN¥463.03 Million | CN¥457.29 Million | CN¥380.35 Million | CN¥286.15 Million |
| Operating Income | CN¥369.11 Million | CN¥344.97 Million | CN¥396.21 Million | CN¥392.91 Million | CN¥321.52 Million |
| EBITDA | CN¥360.81 Million | CN¥338.38 Million | CN¥402.44 Million | CN¥366.11 Million | CN¥294.68 Million |
| EBIT | CN¥317.36 Million | CN¥306.95 Million | CN¥382.07 Million | CN¥346.02 Million | CN¥279.66 Million |
| Interest Expense | CN¥1.33 Million | CN¥1.48 Million | CN¥443.98K | CN¥486.95K | CN¥99.80K |
| Income Before Tax | CN¥365.06 Million | CN¥345.96 Million | CN¥398.75 Million | CN¥393.00 Million | CN¥322.62 Million |
| Income Tax Expense | CN¥60.72 Million | CN¥50.43 Million | CN¥63.02 Million | CN¥66.71 Million | CN¥52.89 Million |
| Net Income | CN¥317.82 Million | CN¥310.18 Million | CN¥348.77 Million | CN¥337.99 Million | CN¥278.45 Million |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | CN¥2.71 Billion | CN¥2.56 Billion | CN¥2.20 Billion | CN¥1.93 Billion | CN¥1.60 Billion |
| Total Current Assets | CN¥1.65 Billion | CN¥1.57 Billion | CN¥1.48 Billion | CN¥1.34 Billion | CN¥1.17 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CN¥196.09 Million | CN¥117.39 Million | CN¥295.05 Million | CN¥370.93 Million | CN¥307.03 Million |
| Net Receivables | CN¥257.87 Million | CN¥202.92 Million | CN¥274.12 Million | CN¥249.26 Million | CN¥226.70 Million |
| Inventory | CN¥57.73 Million | CN¥59.04 Million | CN¥48.41 Million | CN¥53.75 Million | CN¥48.33 Million |
| Property, Plant & Equipment | — | — | CN¥444.61 Million | CN¥301.62 Million | CN¥240.16 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CN¥250.30 Million | CN¥258.46 Million | CN¥170.76 Million | CN¥135.36 Million | CN¥76.61 Million |
| Total Current Liabilities | CN¥182.58 Million | CN¥177.04 Million | CN¥102.75 Million | CN¥108.00 Million | CN¥55.42 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | CN¥-1.10 Billion | CN¥-1.11 Billion | CN¥-824.43 Million | CN¥-642.19 Million | CN¥-573.87 Million |
| Total Stockholder Equity | CN¥2.35 Billion | CN¥2.19 Billion | CN¥1.98 Billion | CN¥1.74 Billion | CN¥1.46 Billion |
| Retained Earnings | CN¥1.43 Billion | CN¥1.26 Billion | CN¥1.09 Billion | CN¥889.64 Million | CN¥647.50 Million |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥262.44 Million | CN¥388.32 Million | CN¥360.28 Million | CN¥360.58 Million | CN¥256.22 Million |
| Capital Expenditures | CN¥117.97 Million | CN¥209.16 Million | CN¥188.74 Million | CN¥122.16 Million | CN¥70.16 Million |
| Free Cash Flow | CN¥144.47 Million | CN¥172.92 Million | CN¥171.54 Million | CN¥238.42 Million | CN¥186.06 Million |
| Investing Cash Flow | CN¥-595.60 Million | CN¥-112.33 Million | CN¥-118.19 Million | CN¥-212.31 Million | CN¥-90.74 Million |
| Financing Cash Flow | CN¥-146.58 Million | CN¥-109.19 Million | CN¥-111.03 Million | CN¥-89.58 Million | CN¥-94.25 Million |
| Dividends Paid | CN¥97.45 Million | CN¥104.72 Million | CN¥105.24 Million | CN¥83.77 Million | CN¥94.25 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | CN¥50.81 Million | CN¥38.46 Million | CN¥26.08 Million | CN¥25.07 Million | CN¥15.03 Million |
| Change in Cash | CN¥-479.73 Million | CN¥166.80 Million | CN¥131.08 Million | CN¥58.67 Million | CN¥71.21 Million |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Oct 24, 2025 | 0.32 | — | — |
| Aug 22, 2025 | 0.20 | — | — |
| Apr 18, 2025 | 0.09 | — | — |
| Oct 24, 2024 | 0.24 | — | — |
| Aug 22, 2024 | 0.14 | — | — |
| Apr 18, 2024 | 0.15 | — | — |
| Oct 25, 2023 | 0.23 | — | — |
| Aug 24, 2023 | 0.15 | — | — |